Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 6/2013

01-12-2013 | Review

Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach

Authors: Yao Dai, Dongsheng Dai, Federico Mercanti, Zufeng Ding, Xianwei Wang, Jawahar L. Mehta

Published in: Acta Diabetologica | Issue 6/2013

Login to get access

Abstract

Cardiovascular diseases are major killers in all developed societies and rapidly becoming the leading cause of morbidity and mortality in the developing world. Patients with diabetes mellitus are at particular risk of developing cardiovascular diseases. The present treatment options for management of diabetes have expanded since the development of glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. There is a growing body of evidence that these agents may have cardioprotective effects even in patients who do not have diabetes. Here, we discuss this evidence as well as pathways that DPP-4 inhibitors target in the cardiovascular system. These agents over time will find an appropriate place in the management of cardiovascular diseases.
Literature
1.
Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I et al (2008) Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 52:255–262PubMedCrossRef
2.
Krum H, Sobotka P, Mahfoud F, Böhm M, Esler M, Schlaich M (2011) Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 123:209–215PubMedCrossRef
3.
Mital S, Chung WK, Colan SD, Sleeper LA, Manlhiot C, Arrington CB et al (2011) Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle. Circulation 123:2353–2362PubMedCrossRef
4.
Katakami N, Kim YS, Kawamori R, Yamasaki Y et al (2010) The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the diabetic atherosclerosis prevention by cilostazol (DAPC) study: a randomized trial. Circulation 121:2584–2591PubMedCrossRef
5.
Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A et al (2013) Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet 381:639–650PubMedCrossRef
6.
Hlatky MA (2012) Compelling evidence for coronary-bypass surgery in patients with diabetes. N Engl J Med 367:2437–2438PubMedCrossRef
7.
Zheng Z, Chen H, Wang H, Ke B, Zheng B, Li Q et al (2010) Improvement of retinal vascular injury in diabetic rats by statins is associated with the inhibition of mitochondrial reactive oxygen species pathway mediated by peroxisome proliferator-activated receptor gamma coactivator 1alpha. Diabetes 59:2315–2325PubMedCrossRef
8.
Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL et al (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:2667–2677PubMedCrossRef
9.
Beca S, Ahmad F, Shen W, Liu J, Makary S, Polidovitch N et al (2013) Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart. Circ Res 112:289–297PubMedCrossRef
10.
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559PubMedCrossRef
11.
Mannucci E, Dicembrini I (2012) Incretin-based therapies and cardiovascular risk. Curr Med Res Opin 28:715–721PubMedCrossRef
12.
Bao W, Aravindhan K, Alsaid H, Chendrimada T, Szapacs M, Citerone DR et al (2011) Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS ONE 6:e23570PubMedCrossRef
13.
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:2340–2350PubMedCrossRef
14.
Ding L, Zhang J (2012) Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin 33:75–81PubMedCrossRef
15.
Mundil D, Cameron-Vendrig A, Husain M (2012) GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res 9:95–108PubMedCrossRef
16.
Tan TM, Field BC, McCullough KA, Troke RC, Chambers ES, Salem V et al (2013) Coadministration of glucagon-like Peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 62:1131–1138PubMedCrossRef
17.
Zander M, Madsbad S, Deacon CF, Holst JJ (2006) The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes. Diabetologia 49:369–374PubMedCrossRef
18.
Sauvé M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M et al (2010) Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 59:1063–1073PubMedCrossRef
19.
Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y (2010) The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 298:H1454–H1465PubMedCrossRef
20.
Huisamen B, Genis A, Marais E, Lochner A (2011) Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther 25:13–20PubMedCrossRef
21.
Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J et al (2008) Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 51:141–147PubMedCrossRef
22.
Pala L, Pezzatini A, Dicembrini I, Ciani S, Gelmini S, Vannelli BG et al (2012) Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells. Acta Diabetol 49:S59–S63PubMedCrossRef
23.
Matheeussen V, Baerts L, De Meyer G, De Keulenaer G, Van der Veken P, Augustyns K et al (2011) Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem 392:189–198PubMedCrossRef
24.
Ban K, Kim KH, Cho CK, Sauvé M, Diamandis EP, Backx PH et al (2010) Glucagon-like peptide (GLP)-1(9–36) amide-mediated cytoprotection is blocked by exendin (9–39) yet does not require the known GLP-1 receptor. Endocrinology 151:1520–1531PubMedCrossRef
25.
Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L et al (2004) Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110:955–961PubMedCrossRef
26.
Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, Dhindsa S et al (2012) Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 97:198–207PubMedCrossRef
27.
Kim SJ, Nian C, McIntosh CH (2007) Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem 282:34139–34147PubMedCrossRef
28.
Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J et al (2011) Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 54:2649–2659PubMedCrossRef
29.
Bremholm L, Hornum M, Andersen UB, Holst JJ (2010) The effect of glucagon-like peptide-2 on arterial blood flow and cardiac parameters. Regul Pept 159:67–71PubMedCrossRef
30.
Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpé S, De Meester I (2006) Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 52:82–87PubMedCrossRef
31.
Moilanen AM, Rysä J, Mustonen E, Serpi R, Aro J, Tokola H et al (2011) Intramyocardial BNP gene delivery improves cardiac function through distinct context-dependent mechanisms. Circ Heart Fail 4:483–495PubMedCrossRef
32.
Mentlein R, Dahms P, Grandt D, Krüger R (1993) Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49:133–144PubMedCrossRef
33.
Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD et al (2007) Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 13:803–811PubMedCrossRef
34.
Zeng C, Wang X, Liu G, Yang C (2002) Effects of ACE inhibitor and beta-adrenergic blocker on plasma NPY and NPY receptors in aortic vascular smooth muscle cells from SHR and WKY rats. Neuropeptides 36:353–361PubMedCrossRef
35.
Zaruba MM, Theiss HD, Vallaster M, Mehl U, Brunner S, David R et al (2009) Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 4:313–323PubMedCrossRef
36.
Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR (1998) Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393:595–599PubMedCrossRef
37.
Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S et al (2010) The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 33:1607–1609PubMedCrossRef
38.
Jackson EK, Zhang M, Liu W, Mi Z (2007) Inhibition of renal dipeptidyl peptidase IV enhances peptide YY1-36-induced potentiation of angiotensin II-mediated renal vasoconstriction in spontaneously hypertensive rats. J Pharmacol Exp Ther 323:431–437PubMedCrossRef
39.
Wang LH, Ahmad S, Benter IF, Chow A, Mizutani S, Ward PE (1991) Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin converting enzyme. Peptides 12:1357–1364PubMedCrossRef
40.
Theiss HD, Vallaster M, Rischpler C, Krieg L, Zaruba MM, Brunner S et al (2011) Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis. Stem Cell Res 7:244–255PubMedCrossRef
41.
Theiss HD, Brenner C, Engelmann MG, Zaruba MM, Huber B, Henschel V et al (2010) Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)–rationale, design and first interim analysis. Int J Cardiol 145:282–284PubMedCrossRef
42.
Fadini GP, Avogaro A (2013) Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. Atherosclerosis 18
43.
Albiero M, Avogaro A, Fadini GP (2013) Restoring stem cell mobilization to promote vascular repair in diabetes. Vascul Pharmacol 58:253–258PubMedCrossRef
44.
Fadini GP, Albiero M, Seeger F, Poncina N, Menegazzo L, Angelini A et al (2013) Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. Basic Res Cardiol 108:313PubMedCrossRef
45.
Fadini GP, Albiero M, de Kreutzenberg SV, Boscaro E, Cappellari R, Marescotti M et al (2013) Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care 36:943–949PubMedCrossRef
46.
Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z et al (2011) Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124:2338–2349PubMedCrossRef
47.
Ervinna N, Mita T, Yasunari E, Azuma K, Tanaka R, Fujimura S et al (2013) Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology 154:1260–1270PubMedCrossRef
48.
Farr S, Adeli K (2012) Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Curr Opin Lipidol 23:56–61PubMedCrossRef
49.
Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P (2011) Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 13:366–373PubMedCrossRef
50.
Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE et al (2006) Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49:2049–2057PubMedCrossRef
51.
Eliasson B, Möller-Goede D, Eeg-Olofsson K, Wilson C, Cederholm J, Fleck P et al (2012) Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 55:915–925PubMedCrossRef
52.
Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y (2011) DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 58:157–166PubMedCrossRef
53.
Hattori S (2011) Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 58:69–73PubMedCrossRef
54.
Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A et al (2011) Sitagliptin exerts an antiinflammatory action. J Clin Endocrinol Metab 97:3333–3341CrossRef
55.
Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R et al (2013) A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism 62:347–351PubMedCrossRef
56.
Mason RP, Jacob RF, Kubant R, Ciszewski A, Corbalan JJ, Malinski T (2012) Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol 60:467–473PubMedCrossRef
57.
Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX et al (2012) Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 60:833–841PubMedCrossRef
58.
Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H et al (2010) Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010:592760PubMedCrossRef
59.
Pacheco BP, Crajoinas RO, Couto GK, Davel AP, Lessa LM, Rossoni LV et al (2011) Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens 29:520–528PubMedCrossRef
60.
Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA et al (2008) Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 48:592–598PubMedCrossRef
61.
Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T et al (2011) Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 223:133–135PubMedCrossRef
62.
Fadini GP, de Kreutzenberg SV, Gjini R, Avogaro A (2011) The metabolic syndrome influences the response to incretin-based therapies. Acta Diabetol 48:219–225PubMedCrossRef
63.
Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, Rose M et al (2011) Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol 303:F963–F971CrossRef
64.
Gomez N, Touihri K, Matheeussen V, Da Costa AM, Mahmoudabady M, Mathieu M et al (2012) Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail 14:14–21PubMedCrossRef
65.
Lenski M, Kazakov A, Marx N, Böhm M, Laufs U (2011) Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol 51:906–918PubMedCrossRef
66.
Fadini GP, Avogaro A (2011) Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 55:10–16PubMedCrossRef
67.
Yin M, Silljé HH, Meissner M, van Gilst WH, de Boer RA (2011) Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol 10:85PubMedCrossRef
68.
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28:1556–1568PubMedCrossRef
69.
Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I (2010) Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 26:540–549PubMedCrossRef
Metadata
Title
Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach
Authors
Yao Dai
Dongsheng Dai
Federico Mercanti
Zufeng Ding
Xianwei Wang
Jawahar L. Mehta
Publication date
01-12-2013
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 6/2013
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-013-0496-4

Other articles of this Issue 6/2013

Acta Diabetologica 6/2013 Go to the issue

Original Article

Nutritional education and carbohydrate counting in children with type 1 diabetes treated with continuous subcutaneous insulin infusion: the effects on dietary habits, body composition and glycometabolic control

Consensus Paper

Trialogue Plus

Original Article

CD2AP is associated with end-stage renal disease in patients with type 1 diabetes

Original Article

Adiponectin increases glucose-induced insulin secretion through the activation of lipid oxidation

Original Article

Quality of life, impaired vision and social role in people with diabetes: a multicenter observational study

Original Article

Effect of weight loss on sympatho-vagal balance in subjects with grade-3 obesity: restrictive surgery versus hypocaloric diet
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits